Gilead Sciences, Inc.


Market Cap$91.42B

Compare Gilead Sciences

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Gilead Sciences, Inc.Gilead Sciences, Inc.15.63.98%26%3.51.1
marketMarket Avg49.51.28%13%6.20.1
HealthcareHealthcare Avg31.91.26%18%7.50.9

Earnings Call Q4 2023

February 6, 2024 - AI Summary

Gilead Sciences reported strong full-year and fourth quarter performance in 2023, with 7% growth in product sales (excluding Veklury) driven by HIV and Oncology.
HIV sales grew by almost $1 billion, with Biktarvy sales increasing 14% to nearly $12 billion and gaining market share in the US.
Oncology sales grew 37% to almost $3 billion, driven by Kite cell therapies and Trodelvy.
Veklury for COVID-19 contributed $2.2 billion in 2023, exceeding expectations but down year-over-year due to the evolving pandemic.
The company expects at least 10 transformative therapies by 2030 and has a catalyst-rich phase ahead with over 20 updates expected in 2024 across Virology and Oncology.

Target Price by Analysts

4.4% upsideGilead Sciences Target Price DetailsTarget Price

Current Fair Value

4.8% upside

Undervalued by 4.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$91.42 Billion
Enterprise Value$109.54 Billion
Dividend Yield$2.9174 (3.98%)
Earnings per Share$4.66
Outstanding Shares1,246,041,895
Avg 30 Day Volume8,371,582


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio15.56
Price to Sales3.47
Price to Book Ratio4.28
Enterprise Value to Revenue4
Enterprise Value to EBIT11.87
Enterprise Value to Net Income18
Total Debt to Enterprise0.23
Debt to Equity1.12

Revenue Sources

No data

ESG Score

No data

About Gilead Sciences, Inc.

CEO: Daniel O'Day